Logo image of PHAS

PHASEBIO PHARMACEUTICALS INC (PHAS) Stock Fundamental Analysis

NASDAQ:PHAS - Nasdaq - US7172241090 - Common Stock - Currency: USD

0.0701  -0.02 (-26.21%)

After market: 0.0533 -0.02 (-23.97%)

Fundamental Rating

2

Taking everything into account, PHAS scores 2 out of 10 in our fundamental rating. PHAS was compared to 555 industry peers in the Biotechnology industry. The financial health of PHAS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, PHAS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PHAS had negative earnings in the past year.
In the past year PHAS has reported a negative cash flow from operations.
PHAS Yearly Net Income VS EBIT VS OCF VS FCFPHAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

Industry RankSector Rank
ROA -463.95%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHAS Yearly ROA, ROE, ROICPHAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 200 -200

1.3 Margins

Industry RankSector Rank
OM -12738.63%
PM (TTM) -12572.13%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHAS Yearly Profit, Operating, Gross MarginsPHAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

PHAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PHAS has been increased compared to 1 year ago.
PHAS has a better debt/assets ratio than last year.
PHAS Yearly Shares OutstandingPHAS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
PHAS Yearly Total Debt VS Total AssetsPHAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

PHAS has an Altman-Z score of -42.67. This is a bad value and indicates that PHAS is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for PHAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -42.67
ROIC/WACCN/A
WACC8.15%
PHAS Yearly LT Debt VS Equity VS FCFPHAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M

2.3 Liquidity

PHAS has a Current Ratio of 0.47. This is a bad value and indicates that PHAS is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.47 indicates that PHAS may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.47
PHAS Yearly Current Assets VS Current LiabilitesPHAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

PHAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.61%, which is quite impressive.
Looking at the last year, PHAS shows a very negative growth in Revenue. The Revenue has decreased by -92.09% in the last year.
The Revenue has been growing by 152.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.33%
Revenue 1Y (TTM)-92.09%
Revenue growth 3Y152.85%
Revenue growth 5YN/A
Sales Q2Q%-97.99%

3.2 Future

The Earnings Per Share is expected to grow by 10.15% on average over the next years. This is quite good.
Based on estimates for the next years, PHAS will show a very strong growth in Revenue. The Revenue will grow by 59.56% on average per year.
EPS Next Y59.21%
EPS Next 2Y25.98%
EPS Next 3Y19.21%
EPS Next 5Y10.15%
Revenue Next Year-64.49%
Revenue Next 2Y-51.62%
Revenue Next 3Y19.06%
Revenue Next 5Y59.56%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PHAS Yearly Revenue VS EstimatesPHAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
PHAS Yearly EPS VS EstimatesPHAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PHAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHAS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHAS Price Earnings VS Forward Price EarningsPHAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0
PHAS Per share dataPHAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PHAS's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.98%
EPS Next 3Y19.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHAS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHASEBIO PHARMACEUTICALS INC

NASDAQ:PHAS (11/2/2022, 8:00:01 PM)

After market: 0.0533 -0.02 (-23.97%)

0.0701

-0.02 (-26.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2022-08-12/bmo
Earnings (Next)11-22 2022-11-22/amc
Inst Owners4.63%
Inst Owner Change0%
Ins Owners10.5%
Ins Owner Change0%
Market Cap3.50M
Analysts45.71
Price Target1.02 (1355.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)29.53%
Min EPS beat(2)-7.01%
Max EPS beat(2)66.06%
EPS beat(4)1
Avg EPS beat(4)0.43%
Min EPS beat(4)-50.57%
Max EPS beat(4)66.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-85.31%
Min Revenue beat(2)-95.08%
Max Revenue beat(2)-75.53%
Revenue beat(4)0
Avg Revenue beat(4)-82.99%
Min Revenue beat(4)-95.08%
Max Revenue beat(4)-69.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0
EPS(TTM)-2.13
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0.02
BVpS-2.35
TBVpS-2.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -463.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -12738.63%
PM (TTM) -12572.13%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.47
Altman-Z -42.67
F-Score2
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)330.2%
Cap/Depr(5y)263.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.33%
EPS Next Y59.21%
EPS Next 2Y25.98%
EPS Next 3Y19.21%
EPS Next 5Y10.15%
Revenue 1Y (TTM)-92.09%
Revenue growth 3Y152.85%
Revenue growth 5YN/A
Sales Q2Q%-97.99%
Revenue Next Year-64.49%
Revenue Next 2Y-51.62%
Revenue Next 3Y19.06%
Revenue Next 5Y59.56%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.05%
OCF growth 3YN/A
OCF growth 5YN/A